228
Views
11
CrossRef citations to date
0
Altmetric
Original Article

Risk factors for mortality due to Acinetobacter baumannii bacteremia in patients with hematological malignancies – a retrospective study

ORCID Icon, , , , , & show all
Pages 2787-2792 | Received 08 Feb 2019, Accepted 18 Mar 2019, Published online: 24 Apr 2019

References

  • Gu Z, Han Y, Meng T, et al. Risk factors and clinical outcomes for patients with Acinetobacter baumannii bacteremia. Medicine (Baltimore). 2016;95:e2943.
  • Kara Ö, Zarakolu P, Aşçioğlu S, et al. Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies. Infect Dis (Lond). 2015;47:686–693.
  • Kim YJ, Kim SI, Kim YR, et al. Carbapenem-resistant Acinetobacter baumannii: diversity of resistant mechanisms and risk factors for infection. Epidemiol Infect. 2012;140:137–145.
  • Ballouz T, Aridi J, Afif C, et al. Risk factors, clinical presentation, and outcome of Acinetobacter baumannii bacteremia. Front Cell Infect Microbiol. 2017;7:156.
  • Freire MP, de Oliveira Garcia D, Garcia CP, et al. Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia. Clin Microbiol Infect. 2016;22:352–358.
  • Metan G, Demiraslan H, Kaynar LG, et al. Factors influencing the early mortality in haematological malignancy patients with nosocomial Gram negative bacilli bacteraemia: a retrospective analysis of 154 cases. Braz J Infect Dis. 2013;17:143–149.
  • Al-Anazi KA, Al-Jasser AM. Infections caused by Acinetobacter baumannii in recipients of hematopoietic stem cell transplantation. Front Oncol. 2014;4:186.
  • Gulen TA, Guner R, Celikbilek N, et al. Clinical importance and cost of bacteremia caused by nosocomial multi drug resistant Acinetobacter baumannii. Int J Infect Dis. 2015;38:32–35.
  • Nazer LH, Kharabsheh A, Rimawi D, et al. Characteristics and outcomes of Acinetobacter baumannii infections in critically ill patients with cancer: a matched case-control study. Microb Drug Resist. 2015;21:556–561.
  • Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309–332.
  • Wang X, Zhang L, Sun A, et al. Acinetobacter baumannii bacteraemia in patients with haematological malignancy: a multicentre retrospective study from the Infection Working Party of Jiangsu Society of Hematology. Eur J Clin Microbiol Infect Dis. 2017;36:1073–1081.
  • Gedik H, Simşek F, Kantürk A, et al. Bloodstream infections in patients with hematological malignancies: which is more fatal – cancer or resistant pathogens? Ther Clin Risk Manag. 2014;10:743–752.
  • Turkoglu M, Mirza E, Tunccan OG, et al. Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit: risk factors and impact on mortality. J Crit Care. 2011;26:460–467.
  • Trecarichi EM, Pagano L, Candoni A, et al. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin Microbiol Infect. 2015;21:337–343.
  • Lee YT, Kuo SC, Yang SP, et al. Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection. Clin Infect Dis. 2012;55:209–215.
  • Liu CP, Shih SC, Wang NY, et al. Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect. 2016;49:934–940.
  • Shorr AF, Zilberberg MD, Micek ST, et al. Predictors of hospital mortality among septic ICU patients with Acinetobacter spp. bacteremia: a cohort study. BMC Infect Dis. 2014;14:572.
  • Erbay A, Idil A, Gozel MG, et al. Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents. 2009;34:575–579.
  • Sunenshine RH, Wright MO, Maragakis LL, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis. 2007;13:97–103.
  • Yahav D, Farbman L, Leibovici L, et al. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect. 2012;18:18–29.
  • Qureshi ZA, Hittle LE, O'Hara JA, et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis. 2015;60:1295–1303.
  • Poole S, Kidd SP, Saeed K. A review of novel technologies and techniques associated with identification of bloodstream infection etiologies and rapid antimicrobial genotypic and quantitative phenotypic determination. Expert Rev Mol Diagn. 2018;18:543–555.
  • Gyssens IC, Kern WV, Livermore DM, et al. The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients. Haematologica. 2013;98:1821–1825.
  • Rosa RG, Goldani LZ, dos Santos RP. Association between adherence to an antimicrobial stewardship program and mortality among hospitalised cancer patients with febrile neutropaenia: a prospective cohort study. BMC Infect Dis. 2014;14:286.
  • Snyder M, Pasikhova Y, Baluch A. Early antimicrobial de-escalation and stewardship in adult hematopoietic stem cell transplantation recipients: retrospective review. Open Forum Infect Dis. 2017;4:ofx226.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.